Cardiology Letters 2019, 28(4):178-183

SynCardia total artificial heart as a bridge to transplant: Current results at the National Institute of Cardiovascular Diseases in Slovakia

Hulman M¹, Artemiou P¹, Hudec V¹, Olejarova I², Goncalvesova E³

¹ Medical Faculty of the Slovak Medical University, National Institute of Cardiovascular Diseases, Clinic of Cardiac Surgery, Bratislava

² Medical Faculty of the Slovak Medical University, National Institute of Cardiovascular Diseases, Department of Anesthesiology, Bratislava

³ Medical Faculty of the Slovak Medical University, National Institute of Cardiovascular Diseases, Clinic of Cardiology, dept. of Heart Failure, Bratislava, Slovakia

In this case series we present our initial experience with the implantation of the SynCardia total artificial heart (TAH) in three patients, the first of which was the first SynCardia TAH implantation in the Visegrad Four (V4) countries. The first and the third patients, after 195 and 126 days of TAH support respectively, experienced successful heart transplants, while the second patient on postoperative day 11 died due to a ruptured undiagnosed brain aneurysm. Our results show that the SynCardia TAH is an alternative therapy in patients with severe end-stage biventricular heart failure waiting for heart transplantation. It is an intermediate step until the development of genetically modified animal hearts, engineered bioartificial hearts or hearts from induced pluripotent stem cells could replace the failing heart in patients with end-stage heart disease. Tab. 2, Fig. 1, Ref. 27, on-line full text (Free, PDF) www.cardiologyletters.sks.sk

Kľúčové slová: biventricular heart failure; total artificial heart; Syncardia TAH; biventricular assist device heart transplantation

Uverejnené: April 1, 2019  Zobraziť citáciu